Loading
Total declarations
Company
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Latest filing published 09 Oct 2020 for Mereo BioPharma Group plc, €25k.
Filing timeline
BuySaleDenise Scots-Knight
Insider track record
Disclosed buys
6
Disclosed sells
0
Signal history
Closed purchases
Market purchases
6
Positive at T+90
67%
Median T+90
+45.7%
Based on 6 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -1.4%Entry US$2.14 · Close at T+365 US$2.11
- -16.3%Entry US$3.55 · Close at T+365 US$2.97
- +30.9%Entry US$2.30 · Close at T+365 US$3.01
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Denise Scots-Knight: trading record in brief
This profile gathers the share dealings of Denise Scots-Knight in Mereo BioPharma Group plc. Over a trading history stretching from 21 May 2019 to 7 October 2020, the count stands at 8 filings.
Purchases make up the whole of the open-market record (6 purchases, €42k). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 2 share grants. Since January 2020: 1 purchase and no sales on the market.
The median purchase comes to €3,767. On 3 out of 6 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. Ninety days after publication, 6 purchases show a median change of +45.7%, with the price up in 67% of them. These figures describe past trades and do not predict future prices.
On 9 October 2020 came the latest disclosure, an open-market purchase for €25k in Mereo BioPharma Group plc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Denise Scots-Knight
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations8 total
12,711 shares@ US$2.3660.5% of flowXNMSFCA-NSM:3744239-0
Canonical exit: 5 Jan 2021 (T+90)
6,000 shares@ £0.5450.0% of flowAIMXFCA-NSM:LSE20190816135146_14192519_20200326185057228_19902-1
Canonical exit: 13 Nov 2019 (T+90)
6,000 shares@ £0.5450.0% of flowAIMXFCA-NSM:LSE20190816135146_14192519_20200326185057228_19902-2
Canonical exit: 14 Nov 2019 (T+90)
87,500 sharesOutside of a trading venueFCA-NSM:LSE20190724100812_14161287_20200326185123408_10441-0
2,000 shares@ £0.456.0% of flowAIMXFCA-NSM:LSE20190719132119_14156640_20200326185123632_15024-0
Canonical exit: 15 Oct 2019 (T+90)
2,000 shares@ US$2.5927.6% of flowXNMSFCA-NSM:LSE20190719132119_14156640_20200326185123632_15024-1
Canonical exit: 17 Oct 2019 (T+90)
8,000 shares@ £0.4524.1% of flowAIMXFCA-NSM:LSE20190719132119_14156640_20200326185123632_15024-2
Canonical exit: 16 Oct 2019 (T+90)
87,500 sharesOutside of a trading venueFCA-NSM:LSE20190521150839_14082298_20200326185142080_11482-0
8 of 8 declarations
